Neurocrine Biosciences stock (US64125C1099): Q1 2026 earnings beat with $815M revenue

Neurocrine Biosciences reported Q1 2026 revenue of $814.5 million, beating expectations, alongside net income of $197.9 million and updates on its neuroscience portfolio.

Neurocrine Biosciences released its first-quarter 2026 earnings on May 8, 2026, posting revenue of $814.5 million and net income of $197.9 million, surpassing analyst forecasts, according to Investing.com as of May 2026. The results highlighted strong performance in its endocrine and neuroscience products, including CRENESSITY, with the stock reacting positively in recent trading.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Neurocrine Biosciences, Inc.
• Sector/industry: Biopharmaceuticals
• Headquarters/country: San Diego, California, USA
• Core markets: United States, international
• Key revenue drivers: Neurological, endocrine, neuropsychiatric treatments
• Home exchange/listing venue: Nasdaq (NBIX)
• Trading currency: USD

Neurocrine Biosciences: core business model

Neurocrine Biosciences is a biopharmaceutical company that discovers, develops, and commercializes treatments for neurological, endocrine, and neuropsychiatric disorders, according to MarketBeat as of 05/11/2026. The firm focuses on conditions like tardive dyskinesia, endometriosis, and Parkinson's disease, leveraging expertise in neurobiology and small-molecule drug development. Its portfolio addresses significant unmet medical needs in these areas.

Main revenue and product drivers for Neurocrine Biosciences

Key products drive revenue through sales of therapies targeting endocrine and neuroscience indications. In Q1 2026, the company reported $814.5 million in revenue for the period ending March 31, 2026, published May 8, 2026, per Simply Wall St as of May 2026. Updates included clinical progress on CRENESSITY and a new obesity candidate NBIP-2118, bolstering its pipeline.

Industry trends and competitive position

The biopharma sector sees rising demand for neurology and endocrine treatments amid aging populations and obesity epidemics in the US. Neurocrine Biosciences holds a competitive edge with approved products and a robust pipeline, projecting $4.1 billion in revenue by 2029 per company narrative cited in Simply Wall St as of May 2026.

Why Neurocrine Biosciences matters for US investors

Listed on Nasdaq, Neurocrine Biosciences offers US investors exposure to innovative therapies addressing domestic health challenges like neurological disorders, which affect millions. Its San Diego base and US-focused markets enhance relevance for American portfolios tracking biotech growth.

Recent stock performance

The stock closed at $150.59 on May 11, 2026, on Nasdaq, down 1.09% for the day, according to MarketBeat as of 05/11/2026. Year-to-date through May 2026, shares rose 6.2% from $141.83. Earlier, on July 22, 2025, NBIX gained 0.698% to $132.75 on Nasdaq per StockInvest.us as of July 2025.

Conclusion

Neurocrine Biosciences delivered a strong Q1 2026 with revenue beats and pipeline advances, supporting its position in biopharma. Trading at around $150 on Nasdaq as of May 11, 2026, the stock reflects ongoing momentum amid sector trends. Investors track upcoming catalysts like further clinical data.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.